Cambridge, UK | 13th August 2016.

 

Isogenica has successfully completed a discovery program with Molecular Templates of Georgetown, TX. Isogenica used its proprietary discovery platform to identify camelid single domain antibodies (VHHs) against two targets selected by Molecular Templates. Molecular Templates has the option to further develop and commercialise antibodies generated from the collaboration, using its proprietary technologies. Isogenica received upfront payments and is eligible for future clinical development milestones and royalties on product sales.